Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 182

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial

Open access
Singh, Jagdeep S.S., Mordi, Ify R., Vickneson, Keeran, Fathi, Amir, Donnan, Peter T., Mohan, Mohapradeep, Choy, Anna Maria J., Gandy, Stephen, George, Jacob, Khan, Faisel, Pearson, Ewan R., Houston, J. Graeme, Struthers, Allan D., Lang, Chim C. · 2020 · Diabetes Care

Abstract

OBJECTIVE: To determine the effects of dapagliflozin in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) on left ventricular (LV) remodeling using cardiac MRI. RESEARCH DESIGN AND METHODS: We randomized 56 patients with T2DM and HF with LV systolic dysfunction to dapagliflozin 10 mg daily or placebo for 1 year, on top of usual therapy. The primary end point was difference in LV end-systolic volume (LVESV) using cardiac MRI. Key secondary end points included other measures of LV remodeling and clinical and biochemical parameters. RESULTS: In our cohort, dapagliflozin had no effect on LVESV or any other parameter of LV remodeling. However, it reduced diastolic blood pressure and loop diuretic requirements while increasing hemoglobin, hematocrit, and ketone bodies. There was a trend toward lower weight. CONCLUSIONS: We were unable to determine with certainty whether dapagliflozin in patients with T2DM and HF had any effect on LV remodeling. Whether the benefits of dapagliflozin in HF are due to remodeling or other mechanisms remains unknown.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc19-2187

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 8

  1. Packer, 2018, Heart failure: the most important, preventable, and treatable cardiovascular complication of type 2 diabetes, Diabetes Care, 41, 11, 10.2337/dci17-0052 · DOI
  2. Singh, 2016, Research into the effect of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design, Cardiovasc Diabetol, 15, 97, 10.1186/s12933-016-0419-0 · DOI
  3. Mordi, 2014, LGE and NT-proBNP identify low risk of death or arrhythmic events in patients with primary prevention ICDs, JACC Cardiovasc Imaging, 7, 561, 10.1016/j.jcmg.2013.12.014 · DOI
  4. Mordi, 2015, The combined incremental prognostic value of LVEF, late gadolinium enhancement, and global circumferential strain assessed by CMR, JACC Cardiovasc Imaging, 8, 540, 10.1016/j.jcmg.2015.02.005 · DOI
  5. Konstam, 2011, Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment, JACC Cardiovasc Imaging, 4, 98, 10.1016/j.jcmg.2010.10.008 · DOI · Paper page
  6. Kramer, 2010, Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach, J Am Coll Cardiol, 56, 392, 10.1016/j.jacc.2010.05.011 · DOI · Paper page
  7. Ferrannini, 2017, Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes, Diabetes Care, 40, 771, 10.2337/dc16-2724 · DOI · Paper page
  8. Lam, 2019, SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects, J Am Heart Assoc, 8, e013389, 10.1161/JAHA.119.013389 · DOI · Paper page

Cited by

See all 182

Metadata

Authors
Singh, J. S. S., Mordi, I. R., Vickneson, K., Fathi, A., Donnan, P. T., Mohan, M., Choy, A. M. J., Gandy, S., George, J., Khan, F., Pearson, E. R., Houston, J. G., Struthers, A. D., & Lang, C. C.
Venue
Diabetes Care
Published
2020-04-03
Volume
43
Issue
6
Pages
1356-1359
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W3015179476
Cited by
182
References
4
FWCI
18.79
Type
journal article
Language
en
Open access
green
Funders
European Foundation for the Study of Diabetes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.